Prevention of Atrial Fibrillation Following Noncardiac Thoracic Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00127712|
Recruitment Status : Completed
First Posted : August 8, 2005
Results First Posted : March 24, 2010
Last Update Posted : September 18, 2013
The investigators hypothesize that the medication amiodarone decreases the incidence of atrial fibrillation (AF) following non-cardiac open-chest surgery. Their specific aims are to:
- Determine the effectiveness of amiodarone for the prevention of AF following non-cardiac open-chest surgery;
- Determine the influence of the prevention of AF following non-cardiac thoracic surgery on post-surgical duration of stay in the Intensive Care Unit (ICU); post-surgical duration of stay in a hospital unit that employs cardiac monitoring; and duration of post-surgical hospital stay; and
- Determine the safety of amiodarone for the prevention of AF following non-cardiac open-chest surgery.
|Condition or disease||Intervention/treatment||Phase|
|Atrial Fibrillation||Drug: Amiodarone||Phase 4|
Thousands of patients undergo major non-cardiac open-chest surgery in the United States each year. These surgeries most often consist of lung surgery, in which one lobe of the lung is removed (lobectomy) or the entire lung is removed (pneumonectomy).
A major complication of these non-cardiac open-chest surgeries is the occurrence of an irregular heartbeat known as atrial fibrillation (AF), which develops in up to 40% of patients undergoing these procedures. AF is characterized by rapid, irregular, chaotic beating of the two smaller chambers of the heart (the atria), leading to rapid, irregular beating of the two larger chambers (the ventricles). The average time to occurrence of post-surgical AF is 2-3 days following surgery. AF occurring following major non-cardiac open-chest surgery can result in extremely rapid heart rates, as fast as 150-200 beats per minute, and may be associated with serious consequences, including severely low blood pressure and potentially debilitating stroke. Further, the risk of death following non-cardiac open-chest surgery is significantly higher in patients who develop AF compared with those who do not. Therefore, the occurrence of this irregular heartbeat following non-cardiac open-chest surgery is associated with severe, potentially life-threatening consequences. Prevention of this irregular heartbeat in these patients may therefore be very important.
Amiodarone is a medication that is known to be effective for prevention and treatment of AF that occurs in patients who have not undergone surgery. In addition, amiodarone has been shown to be effective for prevention of AF following open-chest heart surgery. However, the use of medications for prevention of AF following non-cardiac open-chest surgery has not been well studied, and amiodarone has not been studied in a controlled trial for the prevention of AF in patients undergoing these procedures. In addition, amiodarone is associated with side effects, and it is important to determine the safety of this medication when used in this patient population.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||130 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Prevention of Atrial Fibrillation Following Noncardiac Thoracic Surgery|
|Study Start Date :||September 2004|
|Primary Completion Date :||February 2008|
|Study Completion Date :||February 2008|
Amiodarone 1050 mg via continuous intravenous infusion for 24 hours followed by 400 mg orally twice daily for 6 days
No Intervention: No treatment
Patients in this group receive no intervention
- Incidence of Atrial Fibrillation Requiring Treatment [ Time Frame: 7 days ]
- Incidence of Atrial Fibrillation Lasting Longer Than 30 Seconds [ Time Frame: 7 days ]
- Length of Intensive Care Unit Stay [ Time Frame: Duration of hospitalization ]
- Length of Hospital Stay [ Time Frame: Duration of hospitalization ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00127712
|United States, Indiana|
|Indianapolis, Indiana, United States, 46202|
|Principal Investigator:||James E Tisdale, PharmD||Department of Pharmacy Practice- School of Pharmacy and Pharmacal Sciences- Purdue University|